Abstract
Unlike GLP-1, liraglutide is not cleared by the glomerulus and its pharmacokinetic is not altered in patients with mild renal impairment. The aim of our study was to analyze the effects of liraglutide on renal function in patients with type 2 diabetes. A twelve-month longitudinal prospective post-marketing study was performed. According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min). BMI, glucose, HbA1c, serum creatinine, microalbuminuria, and eGFR were evaluated at baseline and after 12 months of treatment. A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category. Concerning renal function, creatinine levels had a trend to decrease in both groups. eGFR did not change in Group A, while it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters. Moreover, seven out of 41 patients of Group B had increased eGFR levels which reached the normal values (>90 ml/min). At baseline, five patients had pathological microalbuminuria, but at 12 months three of them returned to normal albuminuria (p < 0.006). Total microalbuminuria levels improved in both groups (p < 0.02). According to preliminary data in animals, our study shows that liraglutide is effective in preserving eGFR in diabetic patients, increasing it in those with reduced renal function. This was associated with a decrease of frequency of patients positive to microalbuminuria. Further studies are needed to confirm these data.
Similar content being viewed by others
Abbreviations
- CKD-EPI:
-
Chronic kidney disease epidemiology collaboration
- eGFR:
-
Estimated glomerular filtration rate
- GLP-1:
-
Glucose-like peptide 1
- MDRD:
-
Modification of diet in renal disease
- NO:
-
Nitrogen monoxide
References
M. Malm-Erjefält, I. Bjørnsdottir, J. Vanggaard, H. Helleberg, U. Larsen, B. Oosterhuis, Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab. Dispos. 38(11), 1944–1953 (2010)
J.A. Davidson, J. Brett, A. Falahati, D. Scott, Mild renal impairment and the efficacy and safety of liraglutide. Endocr. Pr. 17(3), 345–355 (2011)
D. Russell-Jones, The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int. J. Clin. Pract. 64(10), 1402–1414 (2010)
S. Madsbad, Liraglutide effect and action in diabetes (LEAD™) trials. Expert Rev. Endocrinol. Metab. 4(2), 119–129 (2009)
J.P. Gutzwiller, S. Tschopp, A. Bock, C.E. Zehnder, A.R. Huber, M. Kreyenbuehl et al., Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89(6), 3055–3061 (2004)
P. Schlatter, C. Beglinger, J. Drewe, H. Gutmann, Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 141(1–3), 120–128 (2007)
R.O. Crajoinas, F.T. Oricchio, T.D. Pessoa, B.P. Pacheco, L.M. Lessa, G. Malnic et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Ren. Physiol. 301(2), 355–363 (2011)
C. Moreno, M. Mistry, R.J. Roman, Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 434(3), 163–167 (2002)
T. Nyström, A.T. Gonon, A. Sjöholm, J. Pernow, Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125(1–3), 173–177 (2005)
C.M. Florkowski, J.S. Chew-Harris, Methods of Estimating GFR - Different Equations Including CKD-EPI. Clin. Biochem. Rev. 32(2), 75–79 (2011)
A.S. Levey, L.A. Stevens, C.H. Schmid, Y. Zhang, A.F. Castro, H.I. Feldman et al., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009)
M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand, M. Zdravkovic et al., LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268–278 (2009)
J.J. Neumiller, T.E. Sonnett, L.D. Wood, S.M. Setter, R.K. Campbell, Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab. Syndr. Obes. 3, 215–226 (2010)
M. Rigato, G.P. Fadini, Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. 7, 107–120 (2014)
G. Aimaretti, Liraglutide: a once-daily human glucagon-like peptide-1 analogue. J. Endocrinol. Invest. 32(8), 701–703 (2009)
R.R. Henry, J.B. Buse, G. Sesti, M.J. Davies, K.H. Jensen, J. Brett et al., Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Endocr. Pract. 17(6), 906–913 (2011)
K.Y. Thong, C. Walton, R. Ryder, Safety and efficacy of liraglutide 1.2 mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit. Prac. Diabetes J. 30(2), 71–76 (2013)
T. Vilsbøll, M. Zdravkovic, T. Le-Thi, T. Krarup, O. Schmitz, J.P. Courrèges et al., Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30(6), 1608–1610 (2007)
B. Wang, J. Zhong, H. Lin, Z. Zhao, Z. Yan, H. He, Y. Ni et al., Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15(8), 737–749 (2013)
L. E. Robinson, T. A. Holt, K. Rees, H. S. Randeva, J. P. O’Hare, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1), e001986 (2013). doi:10.1136/bmjopen-2012-001986
M. Katout, H. Zhu, J. Rutsky, P. Shah, R.D. Brook, J. Zhong et al., Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am. J. Hypertens. 27(1), 130–139 (2014)
K. Okada, K. Kotani, H. Yagyu, A. Ando, J. Osuga, S. Ishibashi, Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine 47(3), 962–964 (2014)
K. Hirata, S. Kume, S. Araki, M. Sakaguchi, M. Chin-Kanasaki, K. Isshiki et al., Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun. 380(1), 44–49 (2009)
P. Anagnostis, V.G. Athyros, F. Adamidou, A. Panagiotou, M. Kita, A. Karagiannis, D.P. Mikhailidis, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes. Metab. 13(4), 302–312 (2011)
L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009)
C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46(3), 406–419 (2014)
W.J. Liu, S.H. Xie, Y.N. Liu, W. Kim, H.Y. Jin, S.K. Park et al., Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 340(2), 248–255 (2012)
H. Zhang, X. Zhang, C. Hu, W. Lu, Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res. 35(6), 483–488 (2012)
M. Haluzík, J. Frolík, I. Rychlík, Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int. J. Endocrinol. (2013). doi:10.1155/2013/895102
C. Pyke, R.S. Heller, R.K. Kirk, C. Orskov, S. Reedtz-Runge, P. Kaastrup et al., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155(4), 1280–1290 (2014)
M.J. Lazzara, W.M. Deen, Model of albumin reabsorption in the proximal tubule. Am. J. Physiol. Renal. Physiol. 292(1), 430–439 (2007)
S.P. Marso, N.R. Poulter, S.E. Nissen, M.A. Nauck, B. Zinman, G.H. Daniels et al., Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am. Heart J. 166(5), 823–830 (2013)
Conflict of interest
The authors declare no conflict of interest. There is not conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Statement of Human and Animal Rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Statement of Informed Consent
Informed consent was obtained from all patients for being included in the study.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zavattaro, M., Caputo, M., Samà, M.T. et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50, 620–626 (2015). https://doi.org/10.1007/s12020-014-0519-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0519-0